A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of a Low-Fat Meal and Evening Dosing on the Pharmacokinetics of KAI-7535 in Healthy Participants Living With Obesity or Overweight
Latest Information Update: 12 Jan 2026
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Kailera Therapeutics
Most Recent Events
- 09 Jan 2026 Status changed from not yet recruiting to recruiting.
- 26 Dec 2025 New trial record